Expert Financial Analysis and Reporting

I have previously written that the Veltassa launch sales figures are not likely to excite investors for some time. However, there is a major catalyst aside from this that could move the stock and that is the May 26th PDUFA date for ZS-9. Here is the issue. The mechanism of action of ZS-9 exchanges sodium […]

Report Overview This blog gives a quick update on my thinking on the 15 stocks which I cover. In most cases, it just offer my opinion with a few supporting thoughts and provides a link to more extensive articles. Also, the reports section of my website has other in-depth reports that you may want to […]

Investment Overview I am interested in Caladrius Biosciences primarily because of the potential for its PCT cell therapy manufacturing business. PCT has a rapidly growing sales base that had $13 million of sales in 2014 and $23 million in 2015. Management is projecting $30 million in 2016. These are all revenues from third parties and do […]

Investment Overview Investors are closely watching the launch progress of Veltassa following its December 2015 introduction. Medicare and managed care have set up barriers to prescribing that makes getting a prescription filled for a new drug laborious and time consuming and sometimes futile. With very few exceptions, most new product launches have disappointed investors to the […]

Investment Thesis for Relypsa The investment issues for Relypsa are complex. Its key drug Veltassa was launched in December of 2015 so that we are now about five months into the launch. Over the last several years it has become increasingly apparent that there is a new paradigm for drug introductions. Managed care has been […]

Investment Thesis The current market valuation of Windtree is only $16 million. This seems extremely low for a Company that is close to having phase 2b data for its key drug Aerosurf. With success in phase 2b, Aerosurf, which potentially has blockbuster commercial potential, will be ready for a phase 3 trial. This key asset […]

Overview In a report published on April 14th I recommended purchasing Chimerix at a price of $5.67. The catalyst for my recommendation was the pending release of data from the AdVise trial of brincidofovir in life threatening adenoviral infections in children and adults. I estimate that the US addressable market for this indication as perhaps $150 […]

Report Overview I usually start my reports with a summary and investment thesis. However, in this report I am putting this section at the end of the report. Northwest issued a press release on May 3 that gave an important operational update on the Company. The press release makes six distinct comments and in this report […]

Overview I listened to CEO Bob Apple speak at the Deutsche Bank conference and wanted to pass along a few pieces of information that are incremental to my recent report. Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 AB EpiPen In regard to AB EpiPen, he said that they are working with Teva […]

I recently wrote a report on Antares entitled Makena has the Potential to Make a Very Significant Contribution to EPS  that highlighted the potentially  significant impact on Antares’ earnings of the subcutaneous formulation of Makena being developed jointly by Antares and AMAG Pharmaceuticals. In a press release summarizing 1Q, 2016 results, AMAG issued some very positive […]